Recent Updates — ITOC
Shareholders approved a 16-for-1 reverse stock split of Class A and Class B ordinary shares, effective October 6, 2026. The consolidation reduces outstanding Class A shares from approximately 109.4 million to roughly 6.8 million and Class B shares from 7.7 million to roughly 479 thousand. Authorized share capital will increase from US$50,000 to US$800,000. The move aims to meet Nasdaq's $1.00 minimum bid price requirement by the October 19 deadline. iTonic Holdings Ltd operates in the healthcare technology industry, developing digital medical solutions and intelligent data platforms.
iTonic Holdings Ltd filed its unaudited financial results for the six months ended June 30, 2026, reporting a net loss of $6,782,691 compared to $2,037,496 in the prior year period. The company recorded significant non-cash charges, including a goodwill impairment loss of $977,841 and an intangible asset impairment loss of $718,258. Revenue increased 49.47% to $100,906, driven by higher sales volume in its treatment planning system (FTTPS) and medical auxiliary supplies. The filing discloses a private investment in public equity (PIPE) financing completed on April 16, 2026, raising $20 million through the issuance of 100,000,000 Class A ordinary shares at $0.20 per share. Additionally, the company paid $20 million in advances for potential acquisitions and announced a shareholder-approved one-for-sixteen reverse stock split effective October 6, 2026, to regain Nasdaq compliance. iTonic Holdings Ltd operates as a healthcare solutions provider specializing in brachytherapy treatment software and devices.
On September 9, 2026, shareholders of iTonic Holdings Ltd approved a reverse stock split consolidating every sixteen existing Class A and Class B ordinary shares into one new share. The consolidation is effective October 6, 2026, subject to Nasdaq notification requirements. Concurrently, the company increased its authorized share capital from US$50,000 (divided into 400 million Class A and 100 million Class B shares) to US$800,000 (divided into 400 million Class A and 100 million Class B shares). The company also adopted a fourth amended and restated memorandum and articles of association to reflect these changes. iTonic Holdings Ltd operates in the technology sector.
iTonic Holdings Ltd announced an extraordinary general meeting for September 9, 2026, to vote on a proposed 1-for-16 reverse stock split effective October 6, 2026, subject to Nasdaq approval. The consolidation reduces the authorized share capital from US$50,000 divided into 400 million Class A and 100 million Class B shares to US$50,000 divided into 25 million Class A and 6.25 million Class B shares. Shareholders will also vote to increase authorized share capital to US$800,000 divided into 400 million Class A and 100 million Class B shares and adopt a fourth amended memorandum and articles of association. The company operates in the technology industry.
On June 18, 2026, Bin Wu resigned as an independent director for personal reasons, stating no disagreement with company operations or policies. Simultaneously, the board appointed Kun Yang as an independent director and member of the Audit, Compensation, and Corporate Governance and Nominating committees. Kun Yang also assumed the role of chair of the Corporate Governance and Nominating Committee. iTonic Holdings Ltd operates in the healthcare industry, providing medical devices and solutions.